Literature DB >> 7773595

The fungal cell wall as a drug target.

N H Georgopapadakou1, J S Tkacz.   

Abstract

Fungal infections are increasingly common and, in certain vulnerable patients, can be serious and even life threatening. The fungal cell wall, a structure with no mammalian counterpart, presents an attractive therapeutic target. Inhibitors of the synthesis of one cell-wall component, beta-(1,3)-glucan, are currently under development as antifungal and antipneumocystis agents.

Entities:  

Mesh：

Substances：

Year:  1995        PMID： 7773595     DOI： 10.1016/s0966-842x(00)88890-3

Source DB:  PubMed          Journal:  Trends Microbiol        ISSN： 0966-842X            Impact factor:   17.079


  51 in total

1.  Proliferation of intrahyphal hyphae caused by disruption of csmA, which encodes a class V chitin synthase with a myosin motor-like domain in Aspergillus nidulans.

Authors:  H Horiuchi; M Fujiwara; S Yamashita; A Ohta; M Takagi
Journal:  J Bacteriol       Date:  1999-06       Impact factor: 3.490

2.  The spheroplast lysis assay for yeast in microtiter plate format.

Authors:  R Ovalle; M Spencer; M Thiwanont; P N Lipke
Journal:  Appl Environ Microbiol       Date:  1999-08       Impact factor: 4.792

3.  Antifungal efficacy of caspofungin (MK-0991) in experimental pulmonary aspergillosis in persistently neutropenic rabbits: pharmacokinetics, drug disposition, and relationship to galactomannan antigenemia.

Authors:  Ruta Petraitiene; Vidmantas Petraitis; Andreas H Groll; Tin Sein; Robert L Schaufele; Andrea Francesconi; John Bacher; Nilo A Avila; Thomas J Walsh
Journal:  Antimicrob Agents Chemother       Date:  2002-01       Impact factor: 5.191

Review 4.  Antifungal agents: chemotherapeutic targets and immunologic strategies.

Authors:  N H Georgopapadakou; T J Walsh
Journal:  Antimicrob Agents Chemother       Date:  1996-02       Impact factor: 5.191

Review 5.  Short native antimicrobial peptides and engineered ultrashort lipopeptides: similarities and differences in cell specificities and modes of action.

Authors:  Maria Luisa Mangoni; Yechiel Shai
Journal:  Cell Mol Life Sci       Date:  2011-05-15       Impact factor: 9.261

6.  Dosage-dependent antifungal efficacy of V-echinocandin (LY303366) against experimental fluconazole-resistant oropharyngeal and esophageal candidiasis.

Authors:  V Petraitis; R Petraitiene; A H Groll; T Sein; R L Schaufele; C A Lyman; A Francesconi; J Bacher; S C Piscitelli; T J Walsh
Journal:  Antimicrob Agents Chemother       Date:  2001-02       Impact factor: 5.191

7.  Efficient bioconversion of echinocandin B to its nucleus by overexpression of deacylase genes in different host strains.

Authors:  Lei Shao; Jian Li; Aijuan Liu; Qing Chang; Huimin Lin; Daijie Chen
Journal:  Appl Environ Microbiol       Date:  2012-12-07       Impact factor: 4.792

Review 8.  Natural products: a continuing source of novel drug leads.

Authors:  Gordon M Cragg; David J Newman
Journal:  Biochim Biophys Acta       Date:  2013-02-18

9.  Characterization of the Escherichia coli Antifungal Protein PPEBL21.

Authors:  V Yadav; R Mandhan; M Kumar; J Gupta; G L Sharma
Journal:  Int J Microbiol       Date:  2010-05-17

10.  Antifungals: need to search for a new molecular target.

Authors:  A T Sangamwar; U D Deshpande; S S Pekamwar
Journal:  Indian J Pharm Sci       Date:  2008 Jul-Aug       Impact factor: 0.975
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.